452 related articles for article (PubMed ID: 18245463)
1. In vivo switching of human melanoma cells between proliferative and invasive states.
Hoek KS; Eichhoff OM; Schlegel NC; Döbbeling U; Kobert N; Schaerer L; Hemmi S; Dummer R
Cancer Res; 2008 Feb; 68(3):650-6. PubMed ID: 18245463
[TBL] [Abstract][Full Text] [Related]
2. Cancer stem cells versus phenotype-switching in melanoma.
Hoek KS; Goding CR
Pigment Cell Melanoma Res; 2010 Dec; 23(6):746-59. PubMed ID: 20726948
[TBL] [Abstract][Full Text] [Related]
3. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.
Tirosh I; Izar B; Prakadan SM; Wadsworth MH; Treacy D; Trombetta JJ; Rotem A; Rodman C; Lian C; Murphy G; Fallahi-Sichani M; Dutton-Regester K; Lin JR; Cohen O; Shah P; Lu D; Genshaft AS; Hughes TK; Ziegler CG; Kazer SW; Gaillard A; Kolb KE; Villani AC; Johannessen CM; Andreev AY; Van Allen EM; Bertagnolli M; Sorger PK; Sullivan RJ; Flaherty KT; Frederick DT; Jané-Valbuena J; Yoon CH; Rozenblatt-Rosen O; Shalek AK; Regev A; Garraway LA
Science; 2016 Apr; 352(6282):189-96. PubMed ID: 27124452
[TBL] [Abstract][Full Text] [Related]
5. MITF in melanoma: mechanisms behind its expression and activity.
Hartman ML; Czyz M
Cell Mol Life Sci; 2015 Apr; 72(7):1249-60. PubMed ID: 25433395
[TBL] [Abstract][Full Text] [Related]
6. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.
Kong X; Kuilman T; Shahrabi A; Boshuizen J; Kemper K; Song JY; Niessen HWM; Rozeman EA; Geukes Foppen MH; Blank CU; Peeper DS
Nature; 2017 Oct; 550(7675):270-274. PubMed ID: 28976960
[TBL] [Abstract][Full Text] [Related]
7. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.
Caramel J; Papadogeorgakis E; Hill L; Browne GJ; Richard G; Wierinckx A; Saldanha G; Osborne J; Hutchinson P; Tse G; Lachuer J; Puisieux A; Pringle JH; Ansieau S; Tulchinsky E
Cancer Cell; 2013 Oct; 24(4):466-80. PubMed ID: 24075834
[TBL] [Abstract][Full Text] [Related]
8. Systematic classification of melanoma cells by phenotype-specific gene expression mapping.
Widmer DS; Cheng PF; Eichhoff OM; Belloni BC; Zipser MC; Schlegel NC; Javelaud D; Mauviel A; Dummer R; Hoek KS
Pigment Cell Melanoma Res; 2012 May; 25(3):343-53. PubMed ID: 22336146
[TBL] [Abstract][Full Text] [Related]
9. Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.
Kemper K; de Goeje PL; Peeper DS; van Amerongen R
Cancer Res; 2014 Nov; 74(21):5937-41. PubMed ID: 25320006
[TBL] [Abstract][Full Text] [Related]
10. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
11. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD
Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800
[TBL] [Abstract][Full Text] [Related]
12. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
Zipser MC; Eichhoff OM; Widmer DS; Schlegel NC; Schoenewolf NL; Stuart D; Liu W; Gardner H; Smith PD; Nuciforo P; Dummer R; Hoek KS
Pigment Cell Melanoma Res; 2011 Apr; 24(2):326-33. PubMed ID: 21176117
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.
O'Connell MP; Marchbank K; Webster MR; Valiga AA; Kaur A; Vultur A; Li L; Herlyn M; Villanueva J; Liu Q; Yin X; Widura S; Nelson J; Ruiz N; Camilli TC; Indig FE; Flaherty KT; Wargo JA; Frederick DT; Cooper ZA; Nair S; Amaravadi RK; Schuchter LM; Karakousis GC; Xu W; Xu X; Weeraratna AT
Cancer Discov; 2013 Dec; 3(12):1378-93. PubMed ID: 24104062
[TBL] [Abstract][Full Text] [Related]
14. Novel MITF targets identified using a two-step DNA microarray strategy.
Hoek KS; Schlegel NC; Eichhoff OM; Widmer DS; Praetorius C; Einarsson SO; Valgeirsdottir S; Bergsteinsdottir K; Schepsky A; Dummer R; Steingrimsson E
Pigment Cell Melanoma Res; 2008 Dec; 21(6):665-76. PubMed ID: 19067971
[TBL] [Abstract][Full Text] [Related]
15. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.
Verfaillie A; Imrichova H; Atak ZK; Dewaele M; Rambow F; Hulselmans G; Christiaens V; Svetlichnyy D; Luciani F; Van den Mooter L; Claerhout S; Fiers M; Journe F; Ghanem GE; Herrmann C; Halder G; Marine JC; Aerts S
Nat Commun; 2015 Apr; 6():6683. PubMed ID: 25865119
[TBL] [Abstract][Full Text] [Related]
16. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
[TBL] [Abstract][Full Text] [Related]
17. Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation.
Suda K; Tomizawa K; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
Lung Cancer; 2012 Jun; 76(3):292-9. PubMed ID: 22133747
[TBL] [Abstract][Full Text] [Related]
18. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
19. Regulation of ferroptotic cancer cell death by GPX4.
Yang WS; SriRamaratnam R; Welsch ME; Shimada K; Skouta R; Viswanathan VS; Cheah JH; Clemons PA; Shamji AF; Clish CB; Brown LM; Girotti AW; Cornish VW; Schreiber SL; Stockwell BR
Cell; 2014 Jan; 156(1-2):317-331. PubMed ID: 24439385
[TBL] [Abstract][Full Text] [Related]
20. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma.
Strub T; Giuliano S; Ye T; Bonet C; Keime C; Kobi D; Le Gras S; Cormont M; Ballotti R; Bertolotto C; Davidson I
Oncogene; 2011 May; 30(20):2319-32. PubMed ID: 21258399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
